Sonia Alix
Institute of Cancer Research(GB)Cancer Research UK(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Biochemical and Molecular Research, Protein Kinase Regulation and GTPase Signaling, Phagocytosis and Immune Regulation, Calcium signaling and nucleotide metabolism
Most-Cited Works
- → The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer(2008)741 cited
- → Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases(2007)349 cited
- → Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
- → Do Alterations in Placental 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activities Explain Differences in Fetal Hypothalamic-Pituitary-Adrenal (HPA) Function Following Periconceptional Undernutrition or Twinning in Sheep?(2009)24 cited
- → Mechanism of Action of AminoCBIs: Highly Reactive but Highly Cytotoxic Analogues of the Duocarmycins(2014)9 cited
- → 96 POSTER Potential importance of the ceramide pathway in the action of the tumour vascular disrupting agent ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid)(2008)3 cited
- → Data from Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases(2023)
- → Data from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2023)
- → Supplementary Figures 1-2 from Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases(2023)
- → Supplementary Figure 3B from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2023)